PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32321768-0	2020	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.	Platinum	23-31	poly(ADP-ribose) polymerase 1	Homo sapiens	165-191	
32321768-1	2020	INTRODUCTION: The introduction of poly-ADP ribose polymerase inhibitors in ovarian cancer has demonstrated significantly improved progression free survival in four randomized controlled clinical trials in patients with platinum sensitive relapsed ovarian cancer.	Platinum	219-227	poly(ADP-ribose) polymerase 1	Homo sapiens	34-60